Studies were included if they: 1) Addressed autoimmune thyroid disease (Hashimoto thyroiditis, Graves’ disease, or related thyroid autoimmunity); 2) Evaluated GLP-1RAs and reported thyroid, hepatic-metabolic, or immune/inflammatory outcomes; or 3) Provided mechanistic or integrative background on adipokines, immunometabolism, gut microbiota, or inflammatory pathways relevant to both GLP-1 biology and AITD. Here, GLP1R is linked to Graves disease.